Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Headlines

EU approves Vertex's next-generation cystic fibrosis drug

Published by Global Banking and Finance Review

Posted on July 1, 2025

Featured image for article about Headlines

(Reuters) -Vertex said on Tuesday that its next-generation drug gained European Commission approval for treating cystic fibrosis, a rare and progressive genetic disease.

The approval expands the company's presence in this market as it combats weak sales of its older cystic fibrosis drug Trikafta.

The new once-daily triple combination therapy, branded Alyftrek, was approved to treat patients aged 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that responds to the therapy.

Cystic fibrosis is an inherited disorder resulting from the absence of a specific protein, which disrupts salt and water movement in and out of cells in various organs.

(Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zahid)